Latest Insider Transactions at Flexion Therapeutics Inc (FLXN)
This section provides a real-time view of insider transactions for Flexion Therapeutics Inc (FLXN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Flexion Therapeutics Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Flexion Therapeutics Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 28
2021
|
Melissa Layman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,624
-2.88%
|
$31,488
$12.55 P/Share
|
|
Jan 27
2021
|
Michael D. Clayman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
119,500
+30.24%
|
-
|
|
Jan 27
2021
|
Melissa Layman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+24.79%
|
-
|
|
Jan 15
2021
|
Samuel D Colella Director |
BUY
Other acquisition or disposition
|
Indirect |
671,060
+38.61%
|
-
|
|
Jan 15
2021
|
Samuel D Colella Director |
SELL
Other acquisition or disposition
|
Indirect |
3,180,675
-81.13%
|
-
|
|
Jan 08
2021
|
Michael D. Clayman President and CEO |
SELL
Bona fide gift
|
Direct |
4,762
-1.28%
|
-
|
|
Jan 05
2021
|
Michael D. Clayman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,530
-1.59%
|
-
|
|
Jan 05
2021
|
David Arkowitz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,073
-3.87%
|
$66,803
$11.13 P/Share
|
|
Jan 05
2021
|
Mark S. Levine General Counsel |
SELL
Open market or private sale
|
Direct |
6,829
-5.98%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Christina Willwerth Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
6,602
-5.42%
|
$72,622
$11.13 P/Share
|
|
Jan 05
2021
|
Kerry Wentworth Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
6,829
-5.66%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Scott Kelley Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,829
-5.67%
|
$75,119
$11.13 P/Share
|
|
Jan 05
2021
|
Adam Muzikant Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,005
-5.17%
|
$44,055
$11.13 P/Share
|
|
Jul 08
2020
|
Michael D. Clayman President and CEO |
SELL
Bona fide gift
|
Direct |
1,303
-0.81%
|
-
|